Spanish BIOBADASER registry real world performance of secukinumab in 639 pts w/ #PsA & spondyloarthritis (axSpA, AS, NR axSpA) showed imprved Dz activity at 1 yr & maintained or increased 2 & 3 years. Retention rates best when SEC used 1st biologic https://t.co/MAE3BhLlRg